This is the only antiarrhythmic agent
ever shown to reduce morbidity and mortality in patients with atrial fibrillation or flutter, said Dr.
Studies have evaluated whether suppressing PVCs with antiarrhythmic agents
They were randomized in double-blind fashion to receive olmesartan at 40 mg/day or placebo and followed for 12 months, during which they were not permitted to be on concomitant antiarrhythmic agents
, other ARBs, or ACE inhibitors.
Amiodarone is widely recognized as the most effective antiarrhythmic agent
at maintaining sinus rhythm in AF patients.
Prism Pharmaceuticals recently received FDA approval for Nexterone[R], an antiarrhythmic agent
which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol[R] formulation technology and licensed to Prism in 2006.
All 3 guidelines, however, state that for the control of symptomatic arrhythmias in heart failure, amiodarone is the antiarrhythmic agent
NYSE: FRX) today announced that its wholly-owned subsidiary Forest Laboratories Holdings Limited and Blue Ash Therapeutics, LLC have entered into an asset purchase agreement, pursuant to which Forest has acquired worldwide rights to azimilide, a novel antiarrhythmic agent
originally developed by Procter & Gamble Pharmaceuticals.
OBJECTIVE To assess antiarrhythmic agent
efficacy for AF conversion and subsequent maintenance of sinus rhythm (MSR).
Food and Drug Administration (FDA) approval for multiple presentations of NEXTERONE[R] (amiodarone HCl), an antiarrhythmic agent
DALLAS -- The novel investigational antiarrhythmic agent
dronedarone reduced by 27% the 1-year combined incidence of hospitalization or death compared with placebo in a large group of patients with paroxysmal or persistent atrial fibrillation, Dr.
BACKGROUND Amiodarone, a class III antiarrhythmic agent
, is effective in the conversion of AF to sinus rhythm.
Carrie is uniquely qualified to help drive our success as we approach the launch of our recently approved product NEXTERONE[R] (amiodarone HCl) Premixed Injection, the first and only premixed intravenous (IV) bag formulation of the antiarrhythmic agent
SHIELD was a double-blind trial involving 633 patients who received an implantable cardioverter defibrillator (ICD) for secondary prevention of cardiac arrest and were randomized to the novel class III antiarrhythmic agent
, azimilide, at 75 or 125 mg/day or to placebo.
Using Captisol enabled Prism Pharmaceuticals to formulate NEXTERONE Premixed Injection without the cosolvents polysorbate 80 and benzyl alcohol used in the innovator product - the antiarrhythmic agent
amiodarone IV originally marketed as Cordarone([R] )Intravenous.
SOFA did not completely shut the door on fish oil as an antiarrhythmic agent